On Decembe 4th, the 8th "Listed Enterprises 2023" award ceremony organized by Bloomberg Businessweek/Chinese Edition was held in Hong Kong. Henlius (2696.HK) has been honored with the "Listed Enterprises 2023" award with its outstanding business performance and comprehensive development potential, being the only biopharmaceutical company on the list.
The "Listed Enterprises 2023" award by Bloomberg Businessweek/Chinese Edition aims to recognize listed enterprises with excellent performance and commend their contributions to the economy. Entries will first be vetted by Bloomberg Terminal data based on eight areas, including business/financial performance, corporate governance, investor relationship, development strategy, corporate social responsibility, sustainability, innovation and risk management. After that, a professional and objective evaluation is carried out by a judging panel composed of government officials, professionals and academics. The "Listed Enterprises 2023" award was conferred upon a total of 11 companies, including China Mobile, Ping An Insurance, China Tower, and Sun Hung Kai Properties, among others.
Nancy Wang, Secretary of Board and Deputy General Manager of Public Communications, said: “We are honored to receive the 'Listed Enterprises 2023' award from Bloomberg Businessweek/Chinese Edition. This recognition fully demonstrates the capital market's high recognition of company’s strength and development potential. In the future, we will continue to integrate our business value with social value, fulfill our corporate social responsibility, constantly surpass ourselves, and achieve sustainable high-quality development."
As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, affordable and innovative biologic medicines to patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. In the first half of 2023, the company achieved profitability for the first time. As of the first three quarters of 2023, the company's annual revenue has exceeded RMB 3.9 billion. The company has achieved continuous profitability through the growth of commercialized revenue from its core products, further validating its integrated biopharmaceutical platform capabilities and self-owned manufacturing strength.
Henlius has always adhered to its mission of “Improving patients' lives by timely providing them with quality and affordable protein therapeutics through technical innovation and operational excellence”. As of now, 5 self-developed products have been launched, benefiting over 495,000 patients and reaching more than 40 markets. Over 10 marketing applications have been accepted for review in the European Union (EU), the United States (U.S.), Canada, Brazil, Columbia, Indonesia, Singapore and other countries and regions.
Furthermore, Henlius places a high emphasis on and actively fulfills corporate social responsibility by integrating philanthropy into its core values and giving back to society. The company has been carrying out the "Rural Medical Service" for three consecutive years, which is dedicated to improving the healthcare infrastructure and quality of care in underserved areas. In 2022, the company launched the “To Time to Life”, a cancer care program, aming to advance cancer prevention and treatment, increasing public and societal awareness of cancer diseases, and promoting the development of cancer prevention and treatment. At the same time, the company was actively involved in pharmaceutical industry exchanges by participating in alliance organizations, academic forums, and industry summits, to foster dialogue between businesses and play a role in advancing the pharmaceutical industry.
In the future, Henlius will continue to adhere to the "patient-centric" principle, increase research and development efforts, establish innovative collaborative platforms, accelerate the translation of achievements, and promote the global reach of products to benefit more patients, achieving high-quality development of the company.